JP2007523210A5 - - Google Patents

Download PDF

Info

Publication number
JP2007523210A5
JP2007523210A5 JP2007500233A JP2007500233A JP2007523210A5 JP 2007523210 A5 JP2007523210 A5 JP 2007523210A5 JP 2007500233 A JP2007500233 A JP 2007500233A JP 2007500233 A JP2007500233 A JP 2007500233A JP 2007523210 A5 JP2007523210 A5 JP 2007523210A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
formulation according
disintegrant
starch
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007500233A
Other languages
English (en)
Japanese (ja)
Other versions
JP4993203B2 (ja
JP2007523210A (ja
Filing date
Publication date
Priority claimed from US10/783,024 external-priority patent/US8642079B2/en
Application filed filed Critical
Publication of JP2007523210A publication Critical patent/JP2007523210A/ja
Publication of JP2007523210A5 publication Critical patent/JP2007523210A5/ja
Application granted granted Critical
Publication of JP4993203B2 publication Critical patent/JP4993203B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007500233A 2004-02-23 2005-01-19 オスペミフェンの固体配合物 Expired - Lifetime JP4993203B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/783,024 US8642079B2 (en) 2004-02-23 2004-02-23 Solid formulations of ospemifene
US10/783,024 2004-02-23
PCT/FI2005/000037 WO2005079777A1 (en) 2004-02-23 2005-01-19 Solid formulations of ospemifene

Publications (3)

Publication Number Publication Date
JP2007523210A JP2007523210A (ja) 2007-08-16
JP2007523210A5 true JP2007523210A5 (https=) 2011-10-06
JP4993203B2 JP4993203B2 (ja) 2012-08-08

Family

ID=34861126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007500233A Expired - Lifetime JP4993203B2 (ja) 2004-02-23 2005-01-19 オスペミフェンの固体配合物

Country Status (19)

Country Link
US (2) US8642079B2 (https=)
EP (2) EP2286806A1 (https=)
JP (1) JP4993203B2 (https=)
CN (1) CN1953741B (https=)
AT (1) ATE506054T1 (https=)
AU (1) AU2005215174B2 (https=)
BR (1) BRPI0507897B8 (https=)
CA (1) CA2554695C (https=)
CY (1) CY1111689T1 (https=)
DE (1) DE602005027540D1 (https=)
DK (1) DK1718288T3 (https=)
ES (1) ES2364970T3 (https=)
MX (1) MXPA06009546A (https=)
NO (1) NO341573B1 (https=)
PL (1) PL1718288T3 (https=)
PT (1) PT1718288E (https=)
RU (2) RU2423113C2 (https=)
SI (1) SI1718288T1 (https=)
WO (1) WO2005079777A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100891887B1 (ko) 2001-01-29 2009-04-03 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2-(1h)-피리돈을 활성 성분으로서 함유하는의약 제제
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
DK1742618T3 (da) 2004-05-04 2012-10-01 Hormos Medical Ltd Flydende orale formuleringer af ospemifen
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101304738A (zh) * 2005-11-09 2008-11-12 霍尔莫斯医疗有限公司 非培米芬的制剂
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
CA2677861C (en) 2007-02-14 2015-05-19 Hormos Medical Ltd. Method for the preparation of therapeutically valuable triphenylbutene derivatives
US7504530B2 (en) 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
WO2009123626A1 (en) * 2008-04-01 2009-10-08 Ocean 1 806, Llc Orodispersable formulations of phosphodiesterase-5 (pde-5) inhibitors
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN104788300B (zh) * 2014-01-22 2017-01-11 南京华威医药科技开发有限公司 欧司哌米芬多晶型
US20160000732A1 (en) * 2014-07-02 2016-01-07 Cadila Healthcare Limited Oral pharmaceutical compositions of ospemifene
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
US10138190B2 (en) 2015-01-09 2018-11-27 Glenmark Pharmaceuticals Limited Process for preparation of ospemifene
AU2016229086B2 (en) * 2015-03-10 2018-12-06 Shionogi Inc. Solid dispersions
US9750716B2 (en) * 2015-03-19 2017-09-05 Wendy Anne Epstein Compounds and forms of treatment for female sexual disorders
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20180206528A1 (en) * 2017-01-24 2018-07-26 Omnigen Research, Llc Granulated feed supplement and methods for making and using
RS63725B1 (sr) 2020-05-18 2022-12-30 Orexo Ab Nova farmaceutska kompozicija za davanje leka
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117121A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. Method of increasing bile flow and decreasing lipid levels
FI100692B (fi) 1994-05-24 1998-02-13 Leiras Oy Menetelmä farmaseuttisten koostumusten valmistamiseksi, jolloin koostu mukset pohjautuvat mikroemulsiogeeleihin sekä uusia mikroemulsioihin p ohjautuvia geelejä
GB9418067D0 (en) 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5597582A (en) 1995-09-12 1997-01-28 Sanofi Oral gel capsule formulation of 1,2,4-benzotriazine oxides
AU718417B2 (en) * 1995-11-14 2000-04-13 Stockhausen Gmbh & Co. Kg Water additive and method for fire prevention and fire extinguishing
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
FI101305B1 (fi) 1996-03-18 1998-05-29 Map Medical Technologies Oy Radiofarmaseuttisena aineena käyttökelpoiset radiojodatut bentsodiatsepiini-johdannaiset ja niiden käyttö diagnostiikassa
DE19653736C2 (de) * 1996-12-12 2002-11-21 Lancaster Group Gmbh Kosmetisches Präparat mit Peptidzusatz
RU2112504C1 (ru) * 1996-12-24 1998-06-10 Открытое акционерное общество "Нижегородский химико-фармацевтический завод" Средство для лечения заболеваний предстательной железы "витапрост"
US6525084B2 (en) * 1998-07-23 2003-02-25 Novo Nordisk A/S Stable pharmaceutical formulation
AU5026599A (en) * 1998-07-23 2000-02-14 Novo Nordisk A/S A wet granulation method for preparing a stable pharmaceutical formulation
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
AU2002235348A1 (en) 2001-01-17 2002-07-30 Praecis Pharmaceuticals Inc. Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
RU2177802C1 (ru) * 2001-01-25 2002-01-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Тетрапептид, регулирующий функции предстательной железы, фармакологическое средство на его основе и способ его применения
US20030055075A1 (en) * 2001-07-13 2003-03-20 Rubsamen Reid M. Programmable controlled release injectable opioid formulation
DE60239207D1 (de) 2001-08-10 2011-03-31 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
HUP0202719A3 (en) 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
SI1509215T1 (sl) 2002-06-06 2007-02-28 Hormos Medical Ltd Zdravljenje ali preprecevanje urogenitalne atrofije in njenih simptomov pri zenskah
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20060105045A1 (en) 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
EA010427B1 (ru) * 2007-04-27 2008-08-29 Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") Средство для лечения заболеваний предстательной железы
RU2430733C2 (ru) * 2009-10-08 2011-10-10 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения заболеваний предстательной железы (варианты)

Similar Documents

Publication Publication Date Title
JP2007523210A5 (https=)
JP6357687B2 (ja) ラコサミドの1日1回投与用製剤
JP6122098B2 (ja) オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物
CA2722093C (en) Pharmaceutical compositions comprising brivaracetam
CA2955495C (en) High dosage strength tablets of rucaparib
CN106943355B (zh) 药物组合物
WO2011111818A1 (ja) モサプリドまたはその塩を含む徐放型医薬組成物
RU2017133990A (ru) Фармацевтические лекарственные формы ингибитора тирозинкиназы брутона
CA2611114A1 (en) An entacapone-containing oral dosage form
JP2007091758A5 (https=)
US20070104785A1 (en) Tablets of linezolid form iii and processes for their preparation
RU2006133902A (ru) Твердые препаративные формы оспемифена
CN104661649A (zh) 包含替格瑞洛的固态口服医药制剂
RU2016117186A (ru) Комбинированная композиция, содержащая тадалафил и амлодипин
JP4970452B2 (ja) メトホルミン徐放性錠剤およびその製造方法
JP2019526591A5 (https=)
JP2020114834A (ja) セリチニブ製剤
JP2008521932A5 (https=)
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
WO2014058047A1 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法
AU2016231883A1 (en) Pharmaceutical compositions of dimethyl fumarate
JP6216408B2 (ja) 固体剤形で非常に難溶性の薬物を調製する方法
WO2005089720A1 (en) Valsartan tablets and the process for the preparation thereof
CN101939002A (zh) 与糖醇共微粉化的恩他卡朋药物组合物
CN105769887A (zh) 一种复方果糖二磷酸钠果糖口崩片及其制备方法